IDEAYA appoints Joshua Bleharski as CFO, effective May 2025

IDEAYA Biosciences, Inc.

Joshua Bleharski, Ph.D., age 50, appointed Chief Financial Officer, effective early May 2025.
Bleharski joins from J.P. Morgan, where he spent 17 years, most recently as Managing Director and Global Co-Head of Biopharma.
Holds B.S. in Biology from Duke, Ph.D. in Immunology from UCLA, and MBA from UC Berkeley Haas.
Compensation terms for Bleharski will be disclosed later via an amendment to this Form 8-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joshua Bleharski

Chief Financial Officer

IDYA · IDEAYA Biosciences, Inc.

Filed: February 10, 2025, 6:59 PM ET

On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Bleharski was appointed as Chief Financial Officer at IDEAYA Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025

View on SEC.gov

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-023076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.